Johnson & Johnson's medical device businesses grew 5.3% on an organic basis in the third quarter, led by the Biosense Webster electrophysiology business. The company is increasing R&D investment, especially in robotic surgery, to boost its surgery and orthopedics businesses.

Johnson & Johnson’s leadership remains optimistic about the future of its medical device divisions despite reporting a 2.6% revenue decline in the first six months of 2019 compared to the same period of 2018.

Four device-related close-out letters were released by FDA in June.

The US market for infection control and biosafety products will see strong growth ahead as hospitals continue the battle against health care-associated infections with innovative products and services designed to prevent needlesticks, nosocomial infections, and the spread of antibiotic-resistant organisms.